Efficacy

ZEJULA extends PARP inhibitor therapy to more women1

Explore the efficacy ZEJULA can offer patients with advanced ovarian cancer in the following indications1:

shadow

FDA-approved indications for ZEJULA1

ZEJULA (niraparib) FDA approved indication chart
ZEJULA (niraparib) FDA approved indication chart

ZEJULA is the only once-daily oral PARP inhibitor for 1L maintenance, regardless of biomarker status1-3

*Status (HRD) was determined using the Myriad™ myChoice CDx as either tBRCA+ and/or GIS+ (genomic instability score [GIS] ≥42). 

1L, first-line; 2L, second-line; 4L, fourth-line; BRCA, breast cancer susceptibility gene; BRCA+, BRCA-mutated; BRCA−, not BRCA-mutated; HRD+, homologous recombination deficiency positive; PARP, poly (ADP-ribose) polymerase; tBRCA, tumor breast cancer susceptibility gene; tBRCA+, tumor BRCA-mutated.

SAFETY DATA

Learn about the safety
and tolerability of ZEJULA

Dose
Modifications

See recommendations for dose adjustments